Artemis Investment Management LLP Has $33.64 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Artemis Investment Management LLP lowered its stake in Natera, Inc. (NASDAQ:NTRA) by 2.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 265,021 shares of the medical research company’s stock after selling 5,317 shares during the quarter. Artemis Investment Management LLP owned about 0.22% of Natera worth $33,644,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Quent Capital LLC increased its holdings in Natera by 3.2% in the first quarter. Quent Capital LLC now owns 3,205 shares of the medical research company’s stock valued at $293,000 after purchasing an additional 99 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after buying an additional 106 shares during the period. Quarry LP increased its stake in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new stake in shares of Natera in the 2nd quarter valued at approximately $28,000. Finally, RiverPark Advisors LLC boosted its stake in Natera by 9.6% during the 2nd quarter. RiverPark Advisors LLC now owns 3,235 shares of the medical research company’s stock worth $350,000 after acquiring an additional 283 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NTRA. Robert W. Baird increased their target price on shares of Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Piper Sandler reaffirmed an “overweight” rating and set a $150.00 price objective on shares of Natera in a research note on Friday, September 13th. Morgan Stanley increased their price target on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. BTIG Research raised their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, TD Cowen lifted their price objective on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and an average target price of $120.07.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 5,496 shares of Natera stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $111.66, for a total transaction of $613,683.36. Following the completion of the sale, the chief executive officer now owns 207,855 shares of the company’s stock, valued at approximately $23,209,089.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, insider Solomon Moshkevich sold 549 shares of the firm’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $105.16, for a total transaction of $57,732.84. Following the transaction, the insider now directly owns 113,637 shares of the company’s stock, valued at approximately $11,950,066.92. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 5,496 shares of Natera stock in a transaction on Monday, July 15th. The shares were sold at an average price of $111.66, for a total value of $613,683.36. Following the completion of the transaction, the chief executive officer now directly owns 207,855 shares of the company’s stock, valued at $23,209,089.30. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 51,738 shares of company stock worth $6,040,584. Company insiders own 7.60% of the company’s stock.

Natera Stock Performance

Shares of NTRA stock opened at $131.93 on Wednesday. The company has a fifty day moving average price of $119.52 and a two-hundred day moving average price of $108.62. Natera, Inc. has a one year low of $36.90 and a one year high of $133.54. The stock has a market cap of $16.20 billion, a P/E ratio of -42.29 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The business had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. Natera’s quarterly revenue was up 58.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.97) earnings per share. As a group, equities analysts predict that Natera, Inc. will post -1.96 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.